BioSyent Inc.

For Q2 2025, BioSyent reported revenue of just over $10 million, up 14% year over year, EBITDA of just under $2.8 million, up 35%, and NIAT of over $2 million, up 28%. EBITDA margin was 27% and NIAT margin was 20%. For the first half, revenue was just over $21 million, up 27%, EBITDA was just under $6 million, up 40%, and NIAT was just over $4.3 million, up 30%, with margins of 28% and 21%, respectively. Looking ahead, management did not give formal numeric guidance, but said momentum has carried into the third quarter and that they expect continued contribution from Tibelia Global and stronger cadence in International Pharma, while Gelclair should remain middling until real-world experience trials are completed.

CEO René Goehrum emphasized that the company is seeing broad-based momentum across Canadian Pharma, International Pharma, and the Legacy business, and said the first half’s growth has carried into the third quarter. He highlighted the company’s long-term strategy of launching and acquiring products while keeping the business profitable, noting 60 consecutive profitable quarters and a growing, diversified portfolio. His tone was confident and upbeat, but measured, especially on product-level variability and the need to refine promotional spending for some brands.

The CFO-style financial commentary focused on strong profitability, margins, cash generation, and capital returns. Management pointed to EBITDA of just under $2.8 million and NIAT of over $2 million in Q2, with margins of 27% and 20%, and said trailing-12-month EPS was $0.72 versus $0.60 a year ago. Cash ended June 30 at just under $27 million, trailing-12-month cash from operations was $12 million, share repurchases totaled $4 million in that period, and dividends returned $2.2 million to shareholders; year to date, 19,500 shares were bought back and the September dividend was set at $0.05, 11% above 2024.

There was no live analyst Q&A in the transcript, but management addressed likely investor questions on tariffs, product performance, and capital allocation. On tariffs, CEO said there has been essentially no direct impact to date, with no expected effect this year, though he acknowledged uncertainty for 2026 and 2027 and said any future impact would depend on Canada-U.S. policy and consumer behavior. He also explained that Gelclair has faced headwinds and that promotional activity has been pulled back pending four real-world experience trials, while FeraMAX remains the core growth brand and a new FeraMAX product is being prepared for 2026.